Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Medical Genetics

Severe Subtypes and the Spectrum of Disease

At a Glance

Dyskeratosis congenita ranges from severe childhood disease to subtle adult-onset lung, liver, or blood problems. Because telomeres and inherited gene changes can affect relatives differently, symptoms may begin earlier, later, or not at all, so family evaluation should involve a genetics team.

While the name “Dyskeratosis Congenita” describes a specific group of physical symptoms, doctors now view it as a broad spectrum of disease. This spectrum ranges from very severe presentations that begin before birth to “cryptic” forms that may not appear until a person is in their 50s or 60s [1][2]. Reading about a severe subtype does not mean you or your child has it unless your clinical team identifies the corresponding findings.

Severe Pediatric Subtypes

In some children, telomeres are critically short early on, affecting the development of the brain, eyes, and immune system. Two of the most serious presentations are Hoyeraal–Hreidarsson syndrome and Revesz syndrome [3][4].

Hoyeraal–Hreidarsson (HH) Syndrome

HH syndrome is typically diagnosed in infancy or early childhood. It is characterized by several specific findings [3][5]:

  • Cerebellar Hypoplasia: The part of the brain that controls balance and coordination (the cerebellum) is smaller than normal [3].
  • Immunodeficiency: Children with HH often have very low levels of certain infection-fighting white blood cells, making them highly susceptible to illness [6].
  • Growth Issues: Many babies with HH have prenatal growth restriction, meaning they were smaller than expected before birth [3].

Revesz Syndrome

Revesz syndrome is very similar to HH but is primarily defined by a specific eye condition called exudative retinopathy [4][7]. Blood vessels in the retina (the back of the eye) grow abnormally and can leak fluid or bleed, which can lead to vision loss if not treated early. Like HH, Revesz syndrome often includes brain calcifications and early bone marrow failure [7][4]. If this syndrome or new vision symptoms are suspected, an individualized ophthalmic assessment is critical.

Adult-Onset and “Cryptic” TBDs

In many adults, a Telomere Biology Disorder (TBD) does not look like “classic” DC. These patients often do not have the lacy skin patches or nail issues. Instead, they may develop what looks like an isolated, “idiopathic” (unexplained) organ problem [2][1].

Common ways “cryptic” TBDs appear in adults include:

  • Idiopathic Pulmonary Fibrosis (IPF): Unexplained scarring of the lungs is a hallmark of adult-onset TBD. It may be the only symptom for many years [8][9].
  • Liver Disease: Some adults develop high blood pressure in the liver (portal hypertension) or scarring (cirrhosis) without a clear cause like alcohol use or hepatitis [10][11].
  • Isolated Blood Disorders: An adult might be diagnosed with “aplastic anemia” or Myelodysplastic Syndrome (MDS), only to find out later it was driven by a telomere defect [12][13].

Why Families Look Different: Anticipation and Penetrance

One of the most confusing parts of TBDs is how differently they can affect people in the same family. A grandfather might have mild lung issues in his 70s, while his grandson faces bone marrow failure at age 10 [14][15]. This happens because of two main factors:

  1. Genetic Anticipation: As a mutation is passed down, telomeres can sometimes be inherited at a shorter length in each generation. This can lead to the disease appearing earlier or being more severe in children than it was in their parents, though it is not inevitable [15][16].
  2. Incomplete Penetrance: Not everyone who carries a TBD-related gene mutation will show symptoms. Someone may be a “silent carrier” but still pass the genetic risk to their children [17][2].

Because of these factors, testing of family members should follow the advice of a genetics team, factoring in informed consent, age, and whether a relative is being evaluated as a potential donor for a bone marrow transplant [18][19].

Common questions in this guide

What is Hoyeraal-Hreidarsson syndrome in dyskeratosis congenita?
Hoyeraal-Hreidarsson syndrome is a severe, early-onset form of dyskeratosis congenita or telomere biology disorder. It may include a small cerebellum, low levels of infection-fighting white blood cells, and poor growth before birth, and it is usually recognized in infancy or early childhood.
How is Revesz syndrome different from Hoyeraal-Hreidarsson syndrome?
Revesz syndrome overlaps with Hoyeraal-Hreidarsson syndrome but is especially associated with exudative retinopathy, in which abnormal retinal blood vessels leak or bleed. It can also involve brain calcifications and early bone marrow failure, so new vision symptoms warrant an individualized ophthalmology evaluation.
Can dyskeratosis congenita first appear in adulthood?
Yes. Some adults do not have classic skin or nail findings and instead develop unexplained lung scarring, portal hypertension or cirrhosis, aplastic anemia, or myelodysplastic syndrome. A telomere biology disorder may be considered when these problems occur without another clear explanation.
Why can telomere disorders become more severe in younger generations?
Genetic anticipation can cause shorter telomeres to be passed to later generations, so symptoms may start earlier or be more severe in a child than in a parent. This pattern is possible but not inevitable, and families should discuss testing and monitoring with a genetics team.
Can someone carry a dyskeratosis congenita-related mutation without symptoms?
Yes. Incomplete penetrance means some people with a telomere-related gene mutation may have few or no symptoms but can still pass the genetic risk to their children. Family testing should be planned with a genetics team, especially when a relative might donate bone marrow.
When should someone with a telomere disorder see an eye specialist?
An individualized ophthalmology assessment is especially important when Revesz syndrome is suspected or when new vision symptoms develop. Exudative retinopathy can involve leaking or bleeding retinal blood vessels and may threaten vision if it is not recognized and treated early.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Do my (or my child's) symptoms lean more toward a specific severe presentation like Hoyeraal-Hreidarsson or Revesz syndrome, and how does that change our monitoring?
  2. 2.Based on my specific phenotype, do I need a specialized ophthalmology assessment to check for retinal issues?
  3. 3.How can we screen other family members for 'cryptic' symptoms, such as premature graying or early lung issues?
  4. 4.If we are considering a bone marrow transplant, how will you ensure a family donor doesn't have 'silent' short telomeres or the same genetic mutation?
  5. 5.Are there specific developmental or neurological evaluations we should start now to monitor for things like cerebellar hypoplasia?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    Dyskeratosis congenita and telomere biology disorders.

    Savage SA

    Hematology. American Society of Hematology. Education Program 2022; (2022(1)):637-648 doi:10.1182/hematology.2022000394.

    PMID: 36485133
  2. 2

    Clinical manifestations of telomere biology disorders in adults.

    Niewisch MR, Beier F, Savage SA

    Hematology. American Society of Hematology. Education Program 2023; (2023(1)):563-572 doi:10.1182/hematology.2023000490.

    PMID: 38066848
  3. 3

    Hoyeraal-Hreidarsson Syndrome due to PARN Mutations: Fourteen Years of Follow-Up.

    Burris AM, Ballew BJ, Kentosh JB, et al.

    Pediatric neurology 2016; (56()):62-68.e1 doi:10.1016/j.pediatrneurol.2015.12.005.

    PMID: 26810774
  4. 4

    Revesz syndrome revisited.

    Karremann M, Neumaier-Probst E, Schlichtenbrede F, et al.

    Orphanet journal of rare diseases 2020; (15(1)):299 doi:10.1186/s13023-020-01553-y.

    PMID: 33097095
  5. 5

    Extended clinical and genetic spectrum associated with biallelic RTEL1 mutations.

    Touzot F, Kermasson L, Jullien L, et al.

    Blood advances 2016; (1(1)):36-46 doi:10.1182/bloodadvances.2016001313.

    PMID: 29296694
  6. 6

    Clinical and Molecular Heterogeneity of RTEL1 Deficiency.

    Speckmann C, Sahoo SS, Rizzi M, et al.

    Frontiers in immunology 2017; (8()):449 doi:10.3389/fimmu.2017.00449.

    PMID: 28507545
  7. 7

    Retinal findings and a novel TINF2 mutation in Revesz syndrome: Clinical and molecular correlations with pediatric retinal vasculopathies.

    Gupta MP, Talcott KE, Kim DY, et al.

    Ophthalmic genetics 2017; (38(1)):51-60 doi:10.1080/13816810.2016.1275019.

    PMID: 28095086
  8. 8

    Diagnosis and Management of Pulmonary Manifestations of Telomere Biology Disorders.

    Del Valle KT, Carmona EM

    Current hematologic malignancy reports 2024; (19(6)):285-292 doi:10.1007/s11899-023-00720-9.

    PMID: 38159192
  9. 9

    Telomeropathies in Interstitial Lung Disease and Lung Transplant Recipients.

    Southern BD, Gadre SK

    Journal of clinical medicine 2025; (14(5)) doi:10.3390/jcm14051496.

    PMID: 40095034
  10. 10

    Telomere biology disorders and hepatic disease.

    Pirzada SA, Aleyadeh W, Fathma S, et al.

    Seminars in hematology 2025; (62(6)):503-512 doi:10.1053/j.seminhematol.2026.05.004.

    PMID: 42215326
  11. 11

    High prevalence of short telomeres in idiopathic porto-sinusoidal vascular disorder.

    Coukos A, Saglietti C, Sempoux C, et al.

    Hepatology communications 2024; (8(8)) doi:10.1097/HC9.0000000000000500.

    PMID: 39037376
  12. 12

    Haematological features of telomere biology disorders diagnosed in adulthood: A French nationwide study of 127 patients.

    Maillet F, Galimard JE, Borie R, et al.

    British journal of haematology 2024; (205(5)):1835-1847 doi:10.1111/bjh.19767.

    PMID: 39279213
  13. 13

    The clinical and laboratory evaluation of patients with suspected hypocellular marrow failure.

    Keel S, Geddis A

    Hematology. American Society of Hematology. Education Program 2021; (2021(1)):134-142 doi:10.1182/hematology.2021000244.

    PMID: 34889426
  14. 14

    The wide-ranging clinical implications of the short telomere syndromes.

    Barbaro PM, Ziegler DS, Reddel RR

    Internal medicine journal 2016; (46(4)):393-403 doi:10.1111/imj.12868.

    PMID: 26247919
  15. 15

    A novel homozygous RTEL1 variant in a consanguineous Lebanese family: phenotypic heterogeneity and disease anticipation.

    Gutierrez-Rodrigues F, Masri N, Chouery E, et al.

    Human genetics 2019; (138(11-12)):1323-1330 doi:10.1007/s00439-019-02076-8.

    PMID: 31677132
  16. 16

    Pulmonary Fibrosis and a TERT Founder Mutation With a Latency Period of 300 Years.

    van der Vis JJ, van der Smagt JJ, Hennekam FAM, et al.

    Chest 2020; (158(2)):612-619 doi:10.1016/j.chest.2020.03.069.

    PMID: 32315675
  17. 17

    Triallelic and epigenetic-like inheritance in human disorders of telomerase.

    Collopy LC, Walne AJ, Cardoso S, et al.

    Blood 2015; (126(2)):176-84 doi:10.1182/blood-2015-03-633388.

    PMID: 26024875
  18. 18

    A Proposed Clinical Diagnostic Framework for Short Telomere Syndrome.

    Courtwright A, King RA, Vagher J, et al.

    Clinical genetics 2026; (110(2)):139-149 doi:10.1111/cge.70190.

    PMID: 42219160
  19. 19

    Unraveling the pathogenesis of Hoyeraal-Hreidarsson syndrome, a complex telomere biology disorder.

    Glousker G, Touzot F, Revy P, et al.

    British journal of haematology 2015; (170(4)):457-71 doi:10.1111/bjh.13442.

    PMID: 25940403

This page explains severe subtypes and adult-onset patterns of dyskeratosis congenita for informational purposes only and does not constitute medical advice. A genetics team and other specialists should interpret your family’s findings and testing.

Get notified when new evidence is published on Dyskeratosis congenita.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.